IGM-7354 is a targeted IL-15 immune stimulating antibody for the treatment of patients with solid and hematologic malignancies. The antibody binding domains of IGM-7354 target PD-L1 on the surface of cells such as cancer cells, to selectively deliver IL-15 in the region of those PD-L1 expressing cells. We believe IGM-7354 may be able to enhance the immune system’s activity in the tumor microenvironment and may also potentially reduce toxicities of this type of therapy in other regions of the body
In 2023, IGM initiated a multicenter, open-label, dose escalation Phase 1 clinical trial to evaluate IGM-7354 intravenously administered as a monotherapy in patients with relapsed and/or refractory solid tumor cancers. The key objectives of this trial are to provide an initial assessment of pharmacokinetics, safety, and immune cell proliferation.